Critical Lessons From High-Value Oncology Practices
نویسندگان
چکیده
منابع مشابه
Low-value practices in oncology contributing to financial toxicity
Financial toxicity of cancer treatment is now a well-recognised problem in cancer medicine leading to patient bankruptcy and even poor survival, including in high-income countries and countries with public health care systems. Many oncologists, despite acknowledging the severity of financial toxicity as a problem, resign the responsibility of reducing the costs of cancer treatment to the govern...
متن کاملLessons learned from radiation oncology clinical trials.
A workshop entitled "Lessons Learned from Radiation Oncology Trials" was held on December 7-8, 2011, in Bethesda, MD, to present and discuss some of the recently conducted radiation oncology clinical trials with a focus on those that failed to refute the null hypothesis. The objectives of this workshop were to summarize and examine the questions that these trials provoked, to assess the quality...
متن کاملTomato Value Chain Information System in Tanzania: Lessons from Kilolo District and Dodoma Municipality, Tanzania
The major challenge for the tomato farmers is getting a fair price at the market price given that there are many actors involved in the tomato value chain. Given this situation, this project's goal was to improve communication pathways in dissemination of agricultural market information in tomato value chains in Iringa and Dodoma Regions in Tanzania. The specific objectives were to: identify an...
متن کاملPrecision and predictive medicine: lessons learned from our oncology colleagues.
A decade ago, a 64-year-old male presenting with fatigue and anemia and a diagnosis suggested of chronic lymphocytic leukemia would be given a standard therapy with an uncertain prognosis. Today, that same patient undergoing molecular profiling of proteins on their lymphocytes detecting ZAP-70 and CD-38 protein markers determines not only the prognosis but how the therapy should be tailored. Th...
متن کاملImmuno-oncology safety education experience: Key lessons from ipilimumab (IPI)
Background IPI (Yervoy, Bristol-Myers Squibb) blocks cytotoxic Tlymphocyte antigen-4, a regulatory molecule on activated T cells. In March 2011, IPI, indicated for unresectable or metastatic melanoma (MEL), became the first immune checkpoint inhibitor approved by the US Food and Drug Administration (FDA). Early in development, severe and fatal immune-related adverse events (irAEs) emerged and w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JAMA Oncology
سال: 2018
ISSN: 2374-2437
DOI: 10.1001/jamaoncol.2017.3803